Abstract
No public abstract is available from the verified source records.
Naeimeh Tavakolinia
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Innate iNKT cells: from biological insight to clinical impact
10.3389/fimmu.2025.1653183 · 2025
Antigen recognition by CD1d-restricted NKT T cell receptors
10.1016/j.smim.2009.10.004 · 2010
Methods for detection, isolation and culture of mouse and human invariant NKT cells
10.1038/nprot.2007.515 · 2008
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells
10.1038/sj.leu.2402943 · 2003
Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein
10.1084/jem.20030324 · 2003
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer
10.1084/jem.20042280 · 2005
Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity
10.1111/j.1600-065x.2007.00561.x · 2007
Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy
10.1182/blood.2022016201 · 2023
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy
10.3389/fimmu.2025.1625426 · 2025
Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia
10.1182/blood.2025029302 · 2026
Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia
10.1038/s41375-026-02930-5 · 2026
Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation
10.1111/j.1537-2995.2009.02395.x · 2010
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism
10.1182/blood-2010-08-303008 · 2011
CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells
10.1182/blood-2014-05-576017 · 2014
Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality
10.1182/blood-2014-11-612762 · 2015
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
10.1182/blood-2011-11-389304 · 2012
Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11
10.1111/j.1365-2567.2007.02647.x · 2007
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load
10.1002/ijc.20998 · 2005
Expansion of human iNKT cells ex vivo
10.1007/978-1-0716-1775-5_11 · 2021
Human and mouse iNKT cell expansion and engineering with viral vectors
2025
Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells
10.1097/01.cji.0000199197.35964.8a · 2006
Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15
10.1016/s0022-1759(00)00272-6 · 2001
Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
10.1186/1471-2172-9-71 · 2008
CD1d-invariant natural killer T cell-based Cancer immunotherapy: alpha-galactosylceramide and beyond
10.3389/fimmu.2018.01519 · 2018
Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
10.1371/journal.pone.0261727 · 2021
Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease
10.1016/j.jcyt.2018.05.007 · 2018
Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop
10.1002/eji.200737389 · 2008
IL-7 during antigenic stimulation using allogeneic dendritic cells promotes expansion of CD45RA(−)CD62L(+)CD4(+) invariant NKT cells with Th-2 biased cytokine production profile
10.3389/fimmu.2020.567406 · 2020
Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials
10.1097/01.cji.0000163593.66910.ad · 2005
Good manufacturing practice and clinical-grade human embryonic stem cell lines
10.1093/hmg/ddn079 · 2008
Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells
2012
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
10.1172/jci83476 · 2016
Human cell-based artificial antigen-presenting cells for cancer immunotherapy
10.1111/imr.12129 · 2014
Cellular therapy: adoptive immunotherapy with expanded natural killer cells
10.1111/imr.12793 · 2019
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy
10.1158/0008-5472.can-08-3712 · 2009
Large-scale expansion of Vgamma9Vdelta2 T cells with engineered K562 feeder cells in G-rex vessels and their use as chimeric antigen receptor-modified effector cells
10.1016/j.jcyt.2017.12.014 · 2018
Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges
10.3389/fmed.2018.00150 · 2018
Good manufacturing practice-compliant production and lot-release of ex vivo expanded regulatory T cells as basis for treatment of patients with autoimmune and inflammatory disorders
10.3389/fimmu.2017.01371 · 2017
Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility
10.1186/s12967-025-06400-x · 2025
Nanoscale artificial antigen presenting cells for T cell immunotherapy
10.1016/j.nano.2013.06.015 · 2014
Serial stimulation of invariant natural killer T cells with covalently stabilized bispecific T-cell engagers generates antitumor immunity while avoiding anergy
10.1158/0008-5472.can-20-2219 · doi-reference
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
10.1007/s00262-012-1381-7 · doi-reference
Development of novel invariant TCR-anchored bispecific engagers to enhance anti-cancer activity of iNKT cells
10.1182/blood-2023-190598 · doi-reference
Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein
10.1182/bloodadvances.2018028886 · doi-reference
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
10.1016/j.ymthe.2024.04.005 · doi-reference
Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence
10.1016/j.omtm.2024.101249 · doi-reference
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
10.1172/jci37869 · doi-reference
Ex-vivo alpha-galactosylceramide activation of NKT cells in humans and macaques
10.1016/j.jim.2012.05.019 · doi-reference
Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial
10.1158/1078-0432.ccr-16-0600 · doi-reference
A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer
10.4049/jimmunol.0800126 · doi-reference
A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer
10.1158/1078-0432.ccr-06-0114 · doi-reference
A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer
10.1158/1078-0432.ccr-04-1453 · doi-reference
Potency assays and biomarkers for cell-based advanced therapy medicinal products
10.3389/fimmu.2023.1186224 · doi-reference
The clinical landscape of CAR-engineered unconventional T cells
10.1016/j.trecan.2025.03.001 · doi-reference
A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and alpha-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: a study protocol
10.1371/journal.pone.0342387 · doi-reference
Pre-clinical evaluation of allogeneic 'off-the-shelf' CAR-iNKT cells targeting CD19 (ALA-101)-expressing hematological malignancies
10.1182/blood-2022-165516 · doi-reference
Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies
10.1016/j.jtct.2023.12.072 · doi-reference
Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
10.1038/s41388-025-03491-0 · doi-reference
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells
10.1038/mt.2013.262 · doi-reference
Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy
10.1038/s41551-026-01629-3 · doi-reference
Barriers and opportunities for CAR T-cell targeting of solid tumors
10.1080/08820139.2022.2096463 · doi-reference
Current challenges and strategies for chimeric antigen receptor-T-cell therapy for solid tumors
10.1615/critrevimmunol.2020036178 · doi-reference
Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy
10.3389/fimmu.2024.1457771 · doi-reference
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome
10.1038/s41467-024-44905-z · doi-reference
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)
10.1038/s41388-024-02948-y · doi-reference
Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP
10.1182/blood-2012-09-456095 · doi-reference
The peripheral differentiation of human natural killer T cells
10.1111/imcb.12248 · doi-reference
Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans
10.1111/imcb.70074 · doi-reference
scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis
10.1016/j.canlet.2023.216149 · doi-reference
Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells
10.1093/jleuko/qiad113 · doi-reference
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors
10.4049/jimmunol.0711086 · doi-reference
Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro
10.4049/jimmunol.1202223 · doi-reference
Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues
10.1016/j.celrep.2025.115587 · doi-reference
Unraveling the phenotypic states of human innate-like T cells: comparative insights with conventional T cells and mouse models
10.1016/j.celrep.2024.114705 · doi-reference
CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells
10.4049/jimmunol.171.5.2571 · doi-reference
Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity
10.1182/blood-2001-12-0196 · doi-reference
Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(−) subsets
10.1111/cei.12045 · doi-reference
Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples
10.1002/eji.200425958 · doi-reference
Thymic development of human natural killer T cells: recent advances and implications for immunotherapy
10.3389/fimmu.2024.1441634 · doi-reference
Ex vivo expansion of Th2-polarizing immunotherapeutic iNKT cells from human peripheral blood
10.1007/978-1-0716-1775-5_13 · doi-reference